Clinical studies of vamorolone

Vamorolone(vamorolone)'s Phase 2a program includes two back-to-back studies involving 48names4 to < 7DMDBoy(vbp 15-002; clinicaltrials.gov NCT 02760264 and vbp 15-003 clinicaltrials.gov NCT 02760277). The 6-month studies investigated oral 0.25, 0.75, 2.0 and Efficacy, safety and tolerability of 6.0 mg/kg/day doses of vamotrolone (12 boys per treatment group). Data from these studies indicate that vamorolone is safe and well-tolerated, with dose- and time-related improvements in various timed functional tests and motor function outcomes over a period of 6 months. Vamotolone treatment resulted in an increase in serum osteocalcin levels, a biomarker of bone formation, suggesting a possible reduction in bone morbidity typically associated with corticosteroids. Biomarker results for adrenal suppression and insulin resistance also suggested that vamorolone treatment was better tolerated relative to published studies of corticosteroid treatment. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.